COMBIGENE Aktie

 

CombiGene is ending its epilepsy program to focus entirely on the COZY pain project for chronic pain treatment. Meanwhile, a cost reduction program is being implemented that is expected to result in net savings of approximately SEK 57 million up to and including Q2 2026. – We want to use our existing cash to increase the company's value as effectively as possible. We believe we can do this by focusing on what we consider to be CombiGene's absolute core competence, says CEO Peter Ekolind. Read the article at biostock.se: https://www.biostock.se/en/2024/10/combigene-implements-cost-savings/...

CombiGene has a clear strategy to identify new, promising projects and academic research collaborations, but also to find a new development partner for the epilepsy project CG01. These objectives were on the agenda when CEO Peter Ekolind presented the company at NLSDays in Malmö. Read the full interview with Peter Ekolind at biostock.se: https://www.biostock.se/en/2024/09/combigenes-ceo-i-am-looking-forward-to-meeting-more-potential-partners/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

CombiGene has published its interim report for the second quarter and substantial emphasis is on the new agreement with Spark concerning the epilepsy project CG01. The company is now focusing on finding a new partner for the project's continued development, while striving to identify new academic collaborations or licensing deals. – During the autumn, we will have access to important data from Spark, and then we can establish the strategy for the epilepsy project CG01, says CEO Peter Ekolind to BioStock. Read the full article at biostock.se: https://www.biostock.se/en/2024/08/continued-...

CombiGene has entered into a new license agreement with Spark Therapeutics regarding intellectual property related to the epilepsy project, CG01. CombiGene's CEO Peter Ekolind believes that they are now in better position to find a new development partner who can take the epilepsy treatment all the way to patients and the market. – We are looking for a partner who can pick up where Spark left off, and with the agreement in place, we can use the data generated over the past two years in our search, says Peter Ekolind. Read the full article at biostock.se (https://www.biostock.se/en/):...

CombiGene's former Director Preclinical Development Annika Ericsson has taken over the role of the company's Chief Scientific Officer. BioStock contacted Ericsson to learn more about her near-term priorities and long-term goals. – We know that CG01 has great potential thanks to the out-licensing to Spark. I also see enormous potential in our pain project, which shows impressive preclinical data, says Annika Ericsson. Read the full interview with Annika Ericsson at biostock.se: https://www.biostock.se/en/2024/05/she-is-combigenes-new-cso/ This is a press release from BioStock -...